About Gimeracil,Oteracil Potassium,Tegafur
            
            Class: | Antineoplastic agent (combination chemotherapy)  
Use: | Treatment of gastric cancer and colorectal cancer, particularly in patients who are not candidates for surgery or have metastatic disease.  
Adult dose: | Typically, the recommended dose is 80 mg/m²/day of Tegafur, administered orally in combination with Gimeracil and Oteracil Potassium, for 28 days followed by a 14-day rest period.  
Pediatric dose: | Safety and efficacy in pediatric patients have not been established; use is not
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent (combination chemotherapy)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of gastric cancer and colorectal cancer, particularly in patients who are not candidates for surgery or have metastatic disease.
                 
                
                
                    
                        Storage Requirements
                    
                    Store at room temperature (15°C to 30°C or 59°F to 86°F) in a tightly closed container, protected from moisture and light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Taiho Pharmaceutical Co. Ltd, JAPAN
                    
                    
                    Package Size
                    56's (14's Blister x 4)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 8372.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Typically, the recommended dose is 80 mg/m²/day of Tegafur, administered orally in combination with Gimeracil and Oteracil Potassium, for 28 days followed by a 14-day rest period.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy in pediatric patients have not been established; use is not recommended.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include nausea, vomiting, diarrhea, fatigue, loss of appetite, and myelosuppression (e.g., leukopenia, anemia, thrombocytopenia).
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to any component of the formulation, severe bone marrow suppression, and pregnancy (due to potential teratogenic effects).
         
        
        
            
                Important Warnings
            
            Monitor for signs of myelosuppression, gastrointestinal toxicity, and potential drug interactions. Use with caution in patients with liver or kidney impairment. Pregnant or breastfeeding women should avoid use due to potential risks to the fetus or infant.
         
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.